ORYZF
Price:
$3.645
Market Cap:
$247.28M
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company dedicated to advancing epigenetics-based therapies for individuals battling cancer and central nervous system (CNS) conditions. The company's clinical pipeline features two key compounds. Iadademstat (ORY-1001), a selective LSD1 inhibitor, is currently undergoing Phase II trials for various oncological indications. Similarly, vafidemstat (ORY-2001), another LSD1 inhibitor specifically designed for CNS applications, is also in Phase II for the treatment of neurological and psychiatric illnesses. Furthermore, ORY-3001, an LSD1 inhibitor, is progressing through preclinical development with the aim of addressing non-cancerous dis...[Read more]
Industry
Biotechnology
IPO Date
2020-12-15
Stock Exchange
OTC
Ticker
ORYZF
According to Oryzon Genomics S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -121.50. This represents a change of -192.99% compared to the average of 130.67 of the last 4 quarters.
The mean historical PE Ratio of Oryzon Genomics S.A. over the last ten years is -41.16. The current -121.50 PE Ratio has changed 29.42% with respect to the historical average. Over the past ten years (40 quarters), ORYZF's PE Ratio was at its highest in in the June 2025 quarter at 415.63. The PE Ratio was at its lowest in in the June 2020 quarter at -163.41.
Average
-41.16
Median
-33.58
Minimum
-88.86
Maximum
-17.06
Discovering the peaks and valleys of Oryzon Genomics S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 315.62%
Maximum Annual PE Ratio = -17.06
Minimum Annual Increase = -78.19%
Minimum Annual PE Ratio = -88.86
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -88.86 | 261.14% |
| 2024 | -24.60 | -32.55% |
| 2023 | -36.48 | 11.06% |
| 2022 | -32.85 | 8.03% |
| 2021 | -30.41 | -44.05% |
| 2020 | -54.35 | 58.35% |
| 2019 | -34.32 | -51.60% |
| 2018 | -70.92 | 315.62% |
| 2017 | -17.06 | -21.55% |
| 2016 | -21.75 | -78.19% |
The current PE Ratio of Oryzon Genomics S.A. (ORYZF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-49.98
5-year avg
-42.64
10-year avg
-41.16
Oryzon Genomics S.A.’s PE Ratio is less than hVIVO plc (-8.92), less than Silence Therapeutics plc (-1.60), less than Santhera Pharmaceuticals Holding AG (-4.17), less than Genfit S.A. (-6.20), less than Transgene S.A. (-2.89), less than Hansa Biopharma AB (publ) (-4.11), less than JW (Cayman) Therapeutics Co. Ltd (-1.00), less than NervGen Pharma Corp. (-8.41), less than China Evergrande New Energy Vehicle Group Limited (-0.13), less than Orpea S.A. (-4.62),
| Company | PE Ratio | Market cap |
|---|---|---|
| -8.92 | $75.45M | |
| -1.60 | $313.17M | |
| -4.17 | $344.83M | |
| -6.20 | $499.80M | |
| -2.89 | $122.57M | |
| -4.11 | $245.80M | |
| -1.00 | $98.91M | |
| -8.41 | $312.89M | |
| -0.13 | $2.17M | |
| -4.62 | $2.29B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oryzon Genomics S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oryzon Genomics S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Oryzon Genomics S.A.'s PE Ratio?
How is the PE Ratio calculated for Oryzon Genomics S.A. (ORYZF)?
What is the highest PE Ratio for Oryzon Genomics S.A. (ORYZF)?
What is the 3-year average PE Ratio for Oryzon Genomics S.A. (ORYZF)?
What is the 5-year average PE Ratio for Oryzon Genomics S.A. (ORYZF)?
How does the current PE Ratio for Oryzon Genomics S.A. (ORYZF) compare to its historical average?